Revenio Group Oyj (HEL:REG1V), a health technology company focussing on ophthalmic products, announced on Monday that it has appointed Mikko Moilanen as the CEO of the company, effective on 5 August 2019.
Timo Hildén, the previous CEO, will continue to lead the integration work of CenterVue acquisition.
Previously, Moilanen was the CEO of Grano Group Oy, owned by the investment company Panostaja Oyj, He also held the position of CEO of Suunto Oy and he has held several international management positions in Nokia Plc.
Revenio Group consists of Icare Finland Oy, Icare USA Inc, Revenio Italy S.R.L, CenterVue SpA, CenterVue Inc, Revenio Research Oy and Oscare Medical Oy.
GelMEDIX completes USD13m seed financing, announces first partnership
AmacaThera named Life Sciences Ontario Emerging Company of the Year
GenSight Biologics reports first patient treated in GS010 REVISE study
Biophytis secures Asian partnership and investment to advance Phase 3 sarcopenia programme
MemorialCare hospitals recognised in 2026 Women's Choice Awards
Champions Oncology expands bioanalytical services with new technology and leadership
PhaseV receives three industry honours for AI in clinical development
Galapagos plans to wind down cell therapy business following strategic review
Sebela's MIUDELLA Hormone-Free Copper IUS recognised in TIME's best inventions of 2025
Revelation Pharma acquires Acacia Apothecary & Wellness
Viatris receives fifth consecutive recognition on Forbes' annual list of World's Best Employers